European Pharmacopoeia Commission Updates Ph.Eur.

News
Article

The European Pharmacopoeia adopts six new texts and revises 31 monographs in its 152nd session.

 

The European Directorate for the Quality of Medicines & HeathCare (EDQM) announced that the European Pharmacopoeia Commission (Ph.Eur.) announced that the commission held its 152nd session in Strasbourg on June 16–17, 2015. The session resulted in six new texts, 31 revised monographs, and six revised general chapters.

The following were included in the updates:

  • A new general monograph on chemical precursors for radiopharmaceutical preparations.

  • A revised chapter on the use of the test for bacterial endotoxins, which includes new recommendations on the need to perform risk assessment when using the bacterial endotoxin test as a pyrogenicity test, due to the potential contamination by nonendotoxin pyrogens; and a section on how to set limits for bacterial endotoxins.

  • A revision to the general chapter on potentiometric determination of pH.

  • A revision to the general chapter on residual solvents to align the latter to the latest version of the ICH Q3C (R5).

  • A revised version of the chapter on pyrogens, which recommends replacing this test by the Monocyte-activation test wherever possible and after product-specific validation to avoid the use of live animals.

The new texts become affective July 1, 2016 and will be published in Supplement 8.8 of the Ph.Eur.

Source: EDQM

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments